01—Abstract
Summary
Summary of the 10-Q filed August 1, 2025. Cited figures are marked; the original filing is the authoritative source.
Linde plc's Q2 2025 10-Q shows steady top-line and profit growth.
Reported sales rose 3% to $8,495 milliona in the quarter (1% year-to-date to $16,607 million), driven by 2% price/mix, 1% cost pass-through and 1% acquisitions, partly offset by 1% lower volumes. Reported operating profit grew 8% to $2,354 million (27.7% margin), and adjusted operating profit (excluding Linde AG merger purchase accounting) rose 6% to $2,556 million with a 30.1% margin. Diluted EPS was $3.73 reported ($4.09 adjusted), up 8% and 6% respectively, helped by a roughly 2% reduction in diluted share count from buybacks.
Cash generation was solid, with operating cash flow of $4,372 millionb for the six months (up 13%), but capital spending rose to $2,527 million, pushing free cash flow lower than the prior-year period after accounting for higher debt-funded investment. Linde returned about $3.6 billion to shareholders in the first half through $2,207 million of net buybacks and $1,412 million of dividends (quarterly dividend raised 8% to $1.50). Total debt increased to $25.9 billion from $21.6 billion at year-end 2024, reflecting new euro, Swiss franc and other bond issuances, though the company retains $6.5 billion of undrawn revolving credit capacity and no financial maintenance covenants.
The most material risk flagged is the Russia-related litigation with RusChemAlliance, where Linde carries $1.9 billionc of recorded liabilities and disclosed contingent liabilities of $1.2 billion (RCA contract terminations) and $0.7 billion (Amur GPP matters). Management does not expect a material adverse impact on earnings, though timing of resolution is uncertain. Other items include a $1.9 billion-plus OBBBA tax benefit expected from 100% bonus depreciation and domestic R&D expensing enacted July 4, 2025, and a backlog of large projects under construction of about $7.1 billion.
02—Key points
Key Highlights
- Q2 2025 reported sales of $8,495M, up 3% YoY; price/mix contributed 2% and acquisitions 1%, while volumes subtracted 1%
- Reported operating profit of $2,354M (+8%) with a 27.7% margin; adjusted operating profit of $2,556M (+6%) with a 30.1% margin
- Diluted EPS of $3.73 reported (+8%) and $4.09 adjusted (+6%), supported by a ~2% reduction in diluted share count
- Operating cash flow of $4,372M for the first half (+13%), while capex rose to $2,527M (+16%), with $2,207M of net share repurchases and $1,412M of dividends
- Total debt increased to $25.9B from $21.6B at year-end 2024 after significant euro, Swiss franc and U.S. dollar bond issuances; $6.5B of revolving credit remains undrawn with no financial maintenance covenants
- Russia litigation with RusChemAlliance remains the key legal exposure, with $1.9B of recorded liabilities and additional contingent liabilities of $1.2B and $0.7B; management expects no material adverse earnings impact
- Subsequent event: OBBBA enacted July 4, 2025, making 100% bonus depreciation and domestic R&D expensing permanent, expected to provide current and future cash tax benefits
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 1, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $8.49B$8.27B | +2.8% |
| R&D Expenses | $38.00M$36.00M | +5.6% |
| SG&A Expenses | $870.00M$840.00M | +3.6% |
| Operating Income | $2.35B$2.18B | +7.8% |
| Net Income | $1.77B$1.66B | +6.2% |
| EPS (Basic) | $3.75$3.46 | +8.4% |
| EPS (Diluted) | $3.73$3.44 | +8.4% |
| Shares Outstanding (Basic) | 470.87M479.97M | −1.9% |
| Shares Outstanding (Diluted) | 473.57M483.18M | −2.0% |
05—Questions
Frequently Asked Questions
How did Linde's second-quarter 2025 profitability compare with the prior year?
Reported operating profit rose 8% to $2,354 million and reported net income attributable to Linde rose 6% to $1,766 million. Adjusted operating profit, which excludes merger purchase accounting and cost reduction charges, rose 6% to $2,556 million, with the adjusted margin expanding to 30.1% from 29.3%. Pricing and productivity gains more than offset cost inflation and lower volumes.
Is Linde's growth coming from pricing or volume?
Growth has come mainly from pricing. In the quarter, price/mix added 2% to sales and volumes subtracted 1%, with acquisitions adding 1% and cost pass-through adding 1%. Volumes were weak in EMEA, where they fell 4%, while Americas volumes grew 1%.
How is Linde funding its capital spending and shareholder returns, and has leverage increased?
Operating cash flow of $4,372 million covered most of the first-half needs, but capex of $2,527 million, acquisitions of $270 million, buybacks of $2,207 million and dividends of $1,412 million required additional funding. Total debt rose to $25.9 billion from $21.6 billion at December 31, 2024, with long-term debt up $4.4 billion and the company issuing new euro-, Swiss franc- and dollar-denominated notes. Management says it has sufficient liquidity and remains committed to its strong credit ratings.
What is the biggest legal or financial risk disclosed in the filing?
The Russia dispute with RusChemAlliance is the largest exposure. Linde has recorded $1.9 billion of liabilities related to the Russia matters, plus contingent liabilities of $1.2 billion for terminated RCA projects and $0.7 billion for Amur GPP claims. Management expects no material adverse earnings impact, but the timing of resolution is difficult to estimate and outcomes could affect results in any given period.
Will the recently enacted tax legislation help Linde's cash flow?
Yes, management expects current and future cash tax benefits from the One Big Beautiful Bill Act, enacted July 4, 2025, which permanently restores 100% bonus depreciation and domestic R&D expensing. These provisions should be favorable given Linde's elevated capex program, though the company has not quantified the benefit in this filing.
06—Continue